Literature DB >> 25499274

NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.

Helen Tucker1, Nwamaka Umeweni2, Janet Robertson2, Jane Adam2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25499274     DOI： 10.1016/S1470-2045(14)71033-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Authors:  Liz Morrell; Sarah Wordsworth; Anna Schuh; Mark R Middleton; Sian Rees; Richard W Barker
Journal:  BMC Health Serv Res       Date:  2018-05-31       Impact factor: 2.655
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.